Abstract
This project's primary goal is to optimize the antineoplastic drug melphalan's performance and the lead compound LASSBio-1735 by developing new crystalline forms and drug release methods. Since melphalan - an antineoplastic drug used to treat breast and ovarian cancer and multiple myeloma - has no known crystal structure, the first stage of this project and, consequently, the first result…